Therefore, the existing reactions give us courage to do more researches in HR+/HER2− advanced breast cancer sequentially.115 However, CDK4/6 inhibitors seem to need a more intact pRb pathway as a mechanism of action, and sometimes that may potentially limit the use in advanced breast cancers. This evidence concerns the gene RB1 and breast carcinoma.